Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 – – Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA – – Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 – – Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 – – Strong Modeyso™ launch with $37 million in revenue in first full quarter on market – – Expect 2026 total revenues of $4.25 to $4.50 billion – DUBLIN, Feb. 24, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026. "2025 was an exceptional year for Jazz, representing our 21st consecutive year of top-line growth and underscoring our commitment to operational excellence as we deliver meaningful innovation for patients," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

PRNewsWire • 6 hours ago

Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago.

Zacks Investment Research • an hour ago

Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • 40 minutes ago

What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings

Evaluate the expected performance of Jazz (JAZZ) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Feb 19, 2026

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 17, 2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 Fireside chat at 7:30 a.m. PT / 10:30 a.m.

PRNewsWire • Feb 17, 2026

Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock?

Investors need to pay close attention to Jazz Pharmaceuticals stock based on the movements in the options market lately.

Zacks Investment Research • Feb 11, 2026

Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.

PRNewsWire • Feb 10, 2026

Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer's ongoing Beamion-BCGC1 trial, evaluating the combination of Boehringer's zongertinib and Jazz's zanidatamab in breast cancer.

GlobeNewsWire • Jan 12, 2026